HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liability Issues Could Arise Under Personal Care Products Safety Act

This article was originally published in The Rose Sheet

Executive Summary

The draft Personal Care Products Safety Act’s safety substantiation requirements – including statements from responsible persons attesting to product safety – are hazily defined and could pose liability risks, in addition to burdens for small companies in particular, EAS consultant John Bailey says. For these reasons and others, the former FDAer is skeptical that industry will support the bill in its current form.

You may also be interested in...



Stakeholders Watching Controversial Personal Care Products Safety Act

The Personal Care Products Act has elicited a mixed reaction from cosmetics stakeholders; as for its prospects, the bill could be "dead on arrival," or it just might pass, according to industry veteran David Steinberg. "The Rose Sheet" is tracking the bill's progress with an updating infographic at therosesheet.com.

Feinstein Bill Lacks ‘Crucial’ National Uniformity Assurance – ICMAD

Small-business trade group the Independent Cosmetic Manufacturers and Distributors says the Personal Care Products Safety Act would place an undue burden on small businesses and fails to address national uniformity issues. In an interview with “The Rose Sheet,” ICMAD President and CEO Pam Busiek discussed the group’s opposition to the bill and suggested that 2012’s Cosmetic Safety Amendments Act would have been a better starting point for legislation.

In Brief: FDA, EPA Sharing Data; Industry Lead-In-Cosmetics Petition Goes Unanswered; More

FDA could use data collected under the Toxic Substances Control Act to inform its risk-assessment work, a March 16 update indicates, announcing a memorandum of understanding between FDA and the Environmental Protection Agency. More news in brief.

Related Content

UsernamePublicRestriction

Register

RS019479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel